Nurohope-CP Tablet is a combination pharmaceutical formulation containing Citicoline 500 mg and Piracetam 800 mg, indicated for the management of cognitive impairments and neurological disorders. Citicoline, a neuroprotective agent, acts as a precursor for the synthesis of phosphatidylcholine, essential for maintaining neuronal membrane integrity and enhancing cerebral metabolism. It facilitates the repair of damaged neuronal membranes and supports neurotransmitter synthesis, thereby improving memory, attention, and overall cognitive function. Piracetam, a nootropic agent, modulates neuronal excitability and enhances synaptic plasticity, contributing to improved learning, memory, and neuroprotection. The synergistic effect of Citicoline and Piracetam in Nurohope-CP Tablet aids in the treatment of conditions such as stroke recovery, dementia, traumatic brain injury, and age-related cognitive decline. This combination is also beneficial in managing symptoms of dyslexia, vertigo, and certain neurodegenerative disorders. Nurohope-CP is generally well tolerated, with a low incidence of adverse effects; however, it should be used under medical supervision, especially in patients with renal impairment or hypersensitivity to the components. Dosage and duration of therapy should be individualized based on clinical response and physician assessment.